Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Momentum Builds To Allow Pre-Tax OTC Purchases Without Prescriptions

This article was originally published in The Tan Sheet

Executive Summary

A bipartisan, bicameral group of lawmakers introduced legislation July 14 to eliminate the prescription requirement to purchase OTC drugs with pre-tax health savings accounts.

You may also be interested in...



GOP Health Care Proposal Cuts Rx Requirement To Buy OTCs With Pre-Tax Savings

Repealing the Affordable Care Act “takes the critical step of restoring the ability to use funds” for OTC drugs “as a qualified medical expense,” say GOP leaders. The proposed legislation also would eliminate a tax on Rx drugs and medical devices that industry negotiated in the creation of ACA.

GOP Health Care Proposal Cuts Rx Requirement To Buy OTCs With Pre-Tax Savings

Repealing the Affordable Care Act “takes the critical step of restoring the ability to use funds” for OTC drugs “as a qualified medical expense,” say GOP leaders. The proposed legislation also would eliminate a tax on Rx drugs and medical devices that industry negotiated in the creation of ACA.

Unfettered OTC Purchasing With Pre-Tax Savings Tops CHPA Goals In 2015

CHPA is optimistic 2015 is the year “common sense” will restore OTC eligibility for health spending accounts. Speaking on the group’s priorities, President and CEO Scott Melville said CHPA will work to improve the OTC monograph system and to curb cough medicine abuse.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel